PDSB

PDS Biotechnology Corp

0.8726

Nov 13 • 3:59 PM ET -0.1074 (-10.96%)

0.8599

Aftermarket • 7:58 PM ET -0.0127 (-1.46%)

Healthcare Biotechnology USA Micro NASD

Nov 13, 10:20 AMPDS Biotechnology reports Q3 2026 non-GAAP EPS of $-0.11 (+42% YoY), misses EPS estimates, while revenue of $0 beats estimates

Peers: INO BCAX PGEN ELTX GLSI IMMP ONCY ANIX MAIA KURA

| Held by: VTI VXF IWC BTEC

Scroll to Statements

Index	-
Market Cap	91.63M
Enterprise Value	76.38M
Income	-32.28M
Sales	0.00M
Book/sh	-0.06
Cash/sh	0.15
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	21
IPO	Oct 01, 2015

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	-
P/C	6.01
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	0.57
Current Ratio	0.57
Debt/Eq	0.00
LT Debt/Eq	0.00
Option/Short	Yes / Yes

EPS (ttm)	-0.55
EPS next Y	-0.13
EPS next Q	-0.06
EPS this Y	45.27%
EPS next Y	67.90%
EPS next 5Y	39.98%
EPS past 3/5Y	19.55% 3.46%
Sales past 3/5Y	- -
EPS Y/Y TTM	30.16%
Sales Y/Y TTM	-
EPS Q/Q	44.90%
Sales Q/Q	-
Earnings	Nov 13 BMO
EPS/Sales Surpr.	-22.22% -

Insider Own	1.73%
Insider Trans	0.00%
Inst Own	25.05%
Inst Trans	5.46%
ROA	-121.19%
ROE	-281.35%
ROIC	-239.22%
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	-26.44%
SMA50	-11.55%
SMA200	3.83%
Trades

Shs Outstand	105.00M
Shs Float	103.19M
Short Float	3.41%
Short Ratio	0.14
Short Interest	3.52M
52W High	1.79 -51.25%
52W Low	0.20 347.03%
Volatility	15.09% 15.80%
ATR (14)	0.18
RSI (14)	40.23
Beta	1.15
Rel Volume	0.24
Avg Volume	25.14M
Volume	5,961,303

Perf Week	-29.06%
Perf Month	-32.88%
Perf Quarter	295.74%
Perf Half Y	-34.88%
Perf YTD	13.35%
Perf Year	3.27%
Perf 3Y	-83.39%
Perf 5Y	-92.39%
Perf 10Y	-99.64%
Recom	1.00
Target Price	4.50
Prev Close	0.98
Price	0.87
Change %	-10.96%

Consensus

Strong Buy

Avg. Price Target

$4.50

Implied Upside

+415.7%

Analysts6incl. previous ratings

Rating Distribution6 Buy · 0 Hold · 0 Sell

Date	Action	Analyst	Rating Change	Price Target Change	Implied Upside
Nov 01, 2022	Initiated	RB. Riley Securities	Buy	$10	+1,046.0%
Jun 28, 2021	Initiated	CCantor Fitzgerald	Overweight	$25	+2,765.0%
Nov 10, 2020	Upgrade	HH.C. Wainwright	Neutral → Buy	$6	+587.6%
May 27, 2020	Initiated	AAlliance Global Partners	Buy	$4	+358.4%
Mar 09, 2020	Initiated	NNoble Capital Markets	Outperform	$5.45	+524.6%
Oct 24, 2019	Initiated	CChardan Capital Markets	Buy	$10	+1,046.0%

Nov-13-26 08:10AM	PDS Biotechnology: Q3 Earnings Snapshot (Associated Press) -10.96%
08:00AM	PDS Biotech Reports Third Quarter 2026 Financial Results (GlobeNewswire)
Nov-10-26 08:00AM	PDS Biotech Announces Exercise of Warrants by NantWorks for Approximately $3.9 Million in Gross Proceeds (GlobeNewswire)
Oct-20-26 08:00AM	PDS Biotechnology Appoints Three Accomplished Pharma Industry Executives to Board of Directors (GlobeNewswire)
Oct-06-26 08:00AM	PDS Biotech to Host Key Opinion Leader Event on PDS0301 for the Treatment of Advanced Colorectal Cancer with Liver Metastases (GlobeNewswire) -12.92%
10:13PM	Loading…
Sep-28-26 10:13PM	KOD Stock Cracks Septembers Top 5 Biotech Gainers On Eye Drug Win But Pharma Bro Shkreli Says It Still Sucks (Stocktwits)
Sep-22-26 08:00AM	PDS Biotech Announces Publication of VERSATILE-002 Phase 2 Clinical Trial Results of PDS0101 with pembrolizumab in HPV16-Positive Recurrent and/or Metastatic (R/M) Head and Neck Cancer in JAMA Oncology (GlobeNewswire) +8.09%
Sep-17-26 03:21AM	This Tiny Biotech Is Beating MRNA, IOVA And SLS Here's How A Billionaire Fueled Its September Rally (Stocktwits) -14.98%
Sep-14-26 07:29PM	IBRX Stock Gains As Soon-Shiongs Nant Capital Backs Second Cancer-Immunotherapy Bet (Stocktwits) +35.33% +46.65%
10:30AM	PDS Biotech Announces Initial Closing of up to $22.3 Million PIPE Financing and the Appointment of Dr. Patrick Soon-Shiong to Its Board of Directors (GlobeNewswire)
Sep-08-26 08:30AM	PDS Biotech Announces up to $22.55 Million Financing Led by Dr. Patrick Soon-Shiong, Founder of NantWorks (GlobeNewswire) +36.36%
Aug-13-26 08:38AM	PDS Biotechnology: Q2 Earnings Snapshot (Associated Press)
08:30AM	PDS Biotech Reports Second Quarter 2026 Financial Results (GlobeNewswire)
Aug-11-26 08:25AM	PDS Biotech Announces Strategic Refocus Prioritizing PDS0301 in Metastatic Colorectal Cancer (mCRC) and Partnership Strategy for PDS0101 (GlobeNewswire) -64.87%
May-13-26 07:02PM	PDS Biotechnology Corp (PDSB) Q1 2026 Earnings Call Highlights: Strategic Advancements and ... (GuruFocus.com) +20.91% +7.52%
07:10AM	Loading…
07:10AM	PDS Biotechnology: Q1 Earnings Snapshot (Associated Press)
07:00AM	PDS Biotech Reports First Quarter 2026 Financial Results and Provides Clinical Programs and Corporate Update (GlobeNewswire)
May-06-26 08:00AM	PDS Biotech Announces Conference Call and Webcast for 2026 First Quarter Financial Results (GlobeNewswire)
Apr-15-26 08:45AM	PDS Biotech Announces Publication of Positive PDS01ADC Interim Phase 2 Clinical Trial Data from Stage 1 of NCI-led Metastatic Colorectal Cancer (mCRC) Trial (GlobeNewswire) +28.30%
Mar-30-26 09:01PM	PDS Biotechnology Corp (PDSB) Q4 2025 Earnings Call Highlights: Financial Discipline Amid ... (GuruFocus.com) +12.77%
07:10AM	PDS Biotechnology: Q4 Earnings Snapshot (Associated Press)
07:00AM	PDS Biotech Reports Full Year 2025 Financial Results and Provides Update on PDS0101 Phase 3 Program and PDS01ADC Clinical Advancement (GlobeNewswire)
Mar-24-26 04:05PM	PDS Biotech Announces Conference Call and Webcast for 2025 Fourth Quarter and Year End Financial Results (GlobeNewswire) +15.38%
Mar-11-26 04:59AM	Mutual Fund vs. ETF: Should You Buy VTSAX or VTI in 2026? (TipRanks)
Feb-20-26 08:30AM	PDS Biotech Announces Adoption of Amended Protocol for Phase 3 VERSATILE-003 Trial Incorporating Progression Free Survival (PFS) as Primary Endpoint for Interim Analysis and Potential Accelerated Approval (GlobeNewswire)
Jan-28-26 08:45AM	PDS Biotech Announces Presentation of Preliminary Results from Phase 2 Study of IL-12 Tumor Targeted Immunocytokine (PDS01ADC) in 3rd Line Metastatic Castration Resistant Prostate Cancer by the NCI (GlobeNewswire)
Jan-22-26 08:45AM	PDS Biotech Announces New U.S. Patent Covering Technology Underlying PDS0101 (GlobeNewswire)
Jan-12-26 10:35AM	Fast-Tracking the $537B Cancer Cure: How Accelerated Approvals Reshaping Oncology in 2026 (PR Newswire) -8.40%
Jan-09-26 08:45AM	PDS Biotech Announces FDA Alignment on use of Progression Free Survival (PFS) as Primary Endpoint (GlobeNewswire) +7.72%
Dec-09-25 08:00AM	PDS Biotech Announces New Composition of Matter Patent for PDS0101 in Japan (GlobeNewswire) +18.00%
12:00PM	Loading…
Dec-08-25 12:00PM	PDS Biotechnology (PDSB) Upgraded to Buy: Here's Why (Zacks)
Dec-02-25 08:30AM	PDS Biotech Announces Scheduling of Type C Meeting with U.S. Food and Drug Administration ("FDA") (GlobeNewswire) +6.95%
Nov-26-25 08:40AM	PDS Biotechnology price target lowered to $3 from $5 at B. Riley (TipRanks) +9.08%
Nov-13-25 02:06PM	PDS Biotechnology Corp (PDSB) Q3 2025 Earnings Call Highlights: Strategic Advances Amid ... (GuruFocus.com) -12.33%
07:40AM	PDS Biotechnology: Q3 Earnings Snapshot (Associated Press Finance)
07:30AM	PDS Biotech Reports Third Quarter 2025 Financial Results and Provides Clinical Programs Update (GlobeNewswire)
Nov-11-25 03:31PM	PDS Biotechnology Announces up to $11.1 Million Registered Direct Offering (GlobeNewswire) +8.75%
Nov-10-25 08:30AM	PDS Biotechnology Announces Translational Data Showing Strong Immunological and Clinical Activity of PDS0101 and PDS01ADC Presented at SITC 2025 (GlobeNewswire) +7.04%
Nov-06-25 08:00AM	PDS Biotech Announces Conference Call and Webcast for Third Quarter 2025 Financial Results (GlobeNewswire)
Oct-30-25 08:00AM	New Clinical and Translational Data on PDS Biotechnology's Novel Investigational Cancer Therapies PDS0101 and PDS01ADC to be Presented at the 2025 Society for Immunotherapy of Cancer (SITC) Annual Meeting (GlobeNewswire) -5.94%
Oct-29-25 08:37AM	PDS Biotech to Seek Expedited Approval Pathway for PDS0101 in HPV16-Positive Head and Neck Cancer (GlobeNewswire) +8.25%
Sep-18-25 08:45AM	PDS Biotech Sets Significant Benchmark in Head and Neck Cancer by Achieving Extended Survival in Low PD-L1 Expression (CPS 1-19) Cohort in VERSATILE-002 Trial, Potentially Eliminating Need for Chemotherapy in the Population (GlobeNewswire)
Sep-02-25 08:00AM	PDS Biotech to Participate in the H.C. Wainwright 27th Annual Global Investment Conference (GlobeNewswire)
Aug-25-25 08:30AM	PDS Biotech Announces Final Topline Survival Data from VERSATILE-002 Phase 2 Trial in Head and Neck Cancer (GlobeNewswire) +9.24%
Aug-14-25 12:30PM	Biotech Stocks Rally as Oncology Market Targets $866B by 2034 (PR Newswire)
Aug-13-25 07:19AM	PDS Biotechnology: Q2 Earnings Snapshot (Associated Press Finance) -5.69%
07:00AM	PDS Biotech Reports Second Quarter 2025 Financial Results and Provides Clinical Programs Update (GlobeNewswire)
Aug-06-25 08:00AM	PDS Biotech Announces Conference Call and Webcast for Second Quarter 2025 Financial Results (GlobeNewswire)
Jul-11-25 07:16AM	PDS Biotechnology completes recruitment for stage one of colorectal cancer trial (Clinical Trials Arena)
Jul-10-25 08:00AM	PDS Biotech Announces Colorectal Cancer Cohort of Phase 2 Clinical Trial with PDS01ADC Met Criteria for Expansion to Stage 2 Following Positive Stage 1 Results (GlobeNewswire)
Jun-09-25 08:00AM	PDS Biotech to Host Key Opinion Leader Event to Discuss Versamune HPV for the Treatment of HPV16+ HNSCC (GlobeNewswire)
Jun-02-25 10:01AM	Take the Zacks Approach to Beat the Markets: StoneCo, Axon, Intuit in Focus (Zacks)
08:00AM	PDS Biotech Unveils Updated Positive Data From VERSATILE-002 Trial and Additional Trials Evaluating Versamune HPV to Treat Head and Neck Cancers at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting (GlobeNewswire)
May-23-25 10:55AM	PDS Biotechnology Corporation (PDSB)'s Versamune HPV Surpasses Survival Benchmarks in Recurrent Head and Neck Cancer Trial (Insider Monkey)
May-22-25 05:26PM	PDS Biotech Announces Positive Extended Follow-Up Data for VERSATILE-002 and Additional Trials Evaluating Versamune HPV to be Presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting (GlobeNewswire)
May-20-25 08:00AM	PDS Biotech to Participate at the A.G.P. Virtual Annual Healthcare Company Showcase (GlobeNewswire) +11.64%
May-15-25 03:09AM	PDS Biotechnology Corp (PDSB) Q1 2025 Earnings Call Highlights: Strategic Advances Amid ... (GuruFocus.com)
01:47AM	Q1 2025 PDS Biotechnology Corp Earnings Call (Thomson Reuters StreetEvents)
May-14-25 07:38AM	PDS Biotechnology: Q1 Earnings Snapshot (Associated Press Finance)
07:30AM	PDS Biotech Reports First Quarter 2025 Financial Results and Provides Clinical Programs and Corporate Update (GlobeNewswire)
May-09-25 04:05PM	PDS Biotechnology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +7.50%
May-08-25 08:00AM	PDS Biotech Announces Additional Details on Two Preclinical Universal Influenza Presentations at IMMUNOLOGY2025 Annual Meeting (GlobeNewswire) +5.17%
May-07-25 08:00AM	PDS Biotech Announces Conference Call and Webcast for First Quarter 2025 Financial Results (GlobeNewswire)
Apr-23-25 10:16AM	PDS Biotech Announces Multiple Abstracts Selected for Presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting (GlobeNewswire) +6.96%
Apr-16-25 08:00AM	PDS Biotech Announces Preclinical Influenza Data to be Presented in Symposium at IMMUNOLOGY2025 Annual Meeting (GlobeNewswire) -6.31%
Apr-08-25 08:00AM	PDS Biotech Announces PDS01ADC Clinical Data to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2025 (GlobeNewswire)
Mar-28-25 03:01AM	PDS Biotechnology Corp (PDSB) Q4 2024 Earnings Call Highlights: Strategic Advances Amid ... (GuruFocus.com)
12:32AM	Q4 2024 PDS Biotechnology Corp Earnings Call (Thomson Reuters StreetEvents)
Mar-27-25 10:35AM	PDS Biotechnology Corporation (PDSB) Q4 2024 Earnings Call Transcript (SeekingAlpha)
07:30AM	PDS Biotech Reports Full Year 2024 Financial Results and Provides Clinical Programs Update (GlobeNewswire)
Mar-25-25 08:00AM	PDS Biotech Leadership to Present at 2025 CAGLA NeauxCancer Conference (GlobeNewswire)
Mar-23-25 08:52AM	PDS Biotechnology (PDSB): Among the Penny Stocks With Huge Upside Potential According to Analysts (InsiderMonkey)
Mar-18-25 08:00AM	PDS Biotech Announces Conference Call and Webcast for Full Year 2024 Financial Results (GlobeNewswire)
Mar-14-25 08:35AM	Life Science Virtual Investor Forum: Presentations Now Available for Online Viewing (GlobeNewswire)
07:22AM	FDA clears PDS Biotechnology's Versamune MUC1 combo for mCRC (Pharmaceutical Business Review)
Mar-13-25 08:00AM	PDS Biotech Announces FDA Clearance of IND Application for Combination of Versamune MUC1 and PDS01ADC to Treat Metastatic Colorectal Cancer (GlobeNewswire) +5.88%
Mar-12-25 01:12PM	Life Sciences Investor Forum Agenda Announced for March 13th (GlobeNewswire)
Mar-11-25 08:00AM	PDS Biotech Leadership to Participate in March Conferences (GlobeNewswire)
Mar-10-25 12:49PM	PDS Biotechnology commences trial for head and neck squamous cell carcinoma (Clinical Trials Arena)
Mar-07-25 08:45AM	PDS Biotech Initiates VERSATILE-003 Phase 3 Clinical Trial Evaluating Versamune HPV in HPV16-Positive Head and Neck Cancer (GlobeNewswire) -8.21%
Feb-27-25 08:00AM	PDS Biotech Announces up to $22 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules (GlobeNewswire) -11.69%
Feb-26-25 08:00AM	PDS Biotech Announces Positive Clinical Data Demonstrating Compelling Survival and Clinical Responses in Recurrent/Metastatic HPV-Associated Cancers Published in JAMA Oncology (GlobeNewswire) +22.22%
Feb-24-25 08:00AM	PDS Biotech Announces Circulating Tumor DNA Results for Versamune HPV in IMMUNOCERV Trial Published in Clinical Cancer Research (GlobeNewswire) -5.22%
Feb-20-25 08:00AM	PDS Biotech to Participate at B. Riley Securities Precision Oncology & Radiopharma Conference 2025 (GlobeNewswire)
Feb-05-25 08:00AM	PDS Biotech Reaffirms Guidance for First Quarter Initiation of VERSATILE-003 Phase 3 Clinical Trial in HPV16-Positive Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (GlobeNewswire)
Dec-06-24 08:00AM	PDS Biotechnology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +8.50%
Dec-03-24 08:00AM	PDS Biotech to Host Key Opinion Leader Event on December 17 at 12 p.m. ET (GlobeNewswire)
Nov-20-24 09:35AM	Down -35.74% in 4 Weeks, Here's Why PDS Biotechnology (PDSB) Looks Ripe for a Turnaround (Zacks)
Nov-15-24 02:08AM	PDS Biotechnology Corp (PDSB) Q3 2024 Earnings Call Highlights: Navigating Financial Challenges ... (GuruFocus.com) -10.67%
Nov-14-24 08:07AM	PDS Biotechnology: Q3 Earnings Snapshot (Associated Press Finance) -18.33%
08:00AM	PDS Biotech Provides Clinical Programs Update and Reports Third Quarter 2024 Financial Results (GlobeNewswire)
Nov-06-24 08:00AM	PDS Biotech to Announce Third Quarter Financial Results on November 14, 2024 at 8:30 a.m. Eastern Time (GlobeNewswire)
Oct-22-24 12:00PM	PDS Biotechnology (PDSB) Upgraded to Strong Buy: Here's What You Should Know (Zacks)
08:00AM	PDS Biotech Announces Presentation of Rationale and Design of First Recurrent Prostate Cancer Trial to Combine an Androgen Receptor Pathway Inhibitor with an Immunocytokine (GlobeNewswire)
Oct-02-24 08:00AM	PDS Biotech Announces 36-Month Overall Survival Rate of 84.4% in Locally Advanced Cervical Cancer Patients Treated with Versamune HPV and Chemoradiation (GlobeNewswire) +12.60%
Sep-16-24 07:00AM	PDS Biotech Announces Updated Results from VERSATILE-002 Phase 2 Clinical Trial Presented at ESMO 2024 (GlobeNewswire)
Sep-09-24 08:00AM	PDS Biotech to Present Updated VERSATILE-002 Data at ESMO Congress 2024 (GlobeNewswire)
Sep-03-24 08:00AM	PDS Biotech to Present at H.C. Wainwright 26th Annual Global Investment Conference (GlobeNewswire) -5.63%
Aug-13-24 08:09AM	PDS Biotechnology: Q2 Earnings Snapshot (Associated Press Finance)
08:00AM	PDS Biotech Provides Business Update and Reports Second Quarter 2024 Financial Results (GlobeNewswire)

Show Previous News

PDS Biotechnology Corp. engages in the development of clinical-stage immunotherapies to treat various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its products include PDS0101 and PDS01ADC. The company was founded by Frank K. Bedu-Addo in 2005 and is headquartered in Princeton, NJ.

FounderDr. Frank K. Bedu-Addo Ph.D.

Chief Medical OfficerDr. Kirk V. Shepard M.D.

Controller & Interim Principal Accounting OfficerMs. Janetta Trochimiuk

Chief Scientific OfficerDr. Gregory L. Conn Ph.D.

Senior VPMr. Spencer Brown J.D.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

All the Features.Half the Price.

PDSB

PDS Biotechnology Corp

Upgrade your Finviz experience

All the Features.
Half the Price.